Safi Biotherapeutics
Safi Biotherapeutics is dedicated to developing on-demand blood cell therapies tailored for individuals in need. As a commercialization partner for a Department of Defense program, the company focuses on overcoming challenges in cell therapy manufacturing, ensuring high consistency and economic viability.
Safi Biotherapeutics
What We Do
Blood Cell Therapies
Safi Biotherapeutics specializes in manufacturing on-demand blood products, including red blood cells for trauma and tailored red blood cells for specific transfusions such as sickle cell disease.
Application Area
Battlefield Resuscitation
Key People
Jon Mogford PhD
Chairman & Co-Founder
Michael Mansour MD, PhD
Co-Founder
Kyle Meetze MBA
COO
Rob Thomas PhD
Scientific Lead
Katie Glen PhD
Lead Biologist
News & Updates
Safi Biotherapeutics has secured funding to enhance its capabilities in growing blood for transfusions.
An article discussing how Safi Biotherapeutics is addressing blood shortages through innovative solutions.
Safi Biotherapeutics has strengthened its position in the market by acquiring EryPharm assets.
A report on technologies developed for effective blood manufacturing in cold weather conditions.
Announcement of the rebranding of Safi Biosolutions to Safi Biotherapeutics.
Safi Biosolutions is working on alternatives to traditional blood donation methods.
Collaboration between iBio and Safi Biosolutions to develop growth factors.
Partnership aimed at developing human blood production technologies.
Discussion on the potential for on-site blood production in combat situations.
An overview of how 4D Bio3 is enhancing care in battlefield conditions.